Regulators order nationwide checks after an expensive specialist medicine intended for Turkey surfaces in Pakistan outside authorized supply channels.
ISLAMABAD, Nov. 18 (Focus Pakistan) — A specialist injection intended for Turkey has surfaced in Pakistan, prompting the country’s drug regulator to order a nationwide search for a suspected fake Novartis injection.
The Drug Regulatory Authority of Pakistan (DRAP) issued Rapid Alert No. I/S/11-26-59 on Tuesday, Nov. 17, against the Sandostatin LAR 20 mg injection, batch 380531. It filed the product under its spurious or falsified category. It told federal and provincial drug-control teams to survey the supply chain, trace the batch, and seize what they find.
The alert traces back to Karachi. Nouveaux Pharma Limited, which holds the Pakistani marketing license, told DRAP the batch came from stock meant for Turkey. The company said it never supplied that batch to Pakistan through legal channels.
One batch under scrutiny, not the entire brand
DRAP’s notice lists Novartis Pharmaceutical Manufacturing GmbH of Austria as the manufacturer in the product information. It does not accuse the company of making a counterfeit. The notice contains no laboratory results showing wrong ingredients, and DRAP has reported no confirmed patient injuries. The warning rests on the route. The batch reached Pakistan outside its authorized supplier, and DRAP says that raises doubts about its authenticity, quality, and safety.
Also Read: DRAP Orders Recall of Two Medicines After Punjab Labs Find Quality Failures
The wording matters. The World Health Organization defines falsified medical products as those that deliberately or fraudulently misrepresent their identity, composition, or source, and it class unregistered or unlicensed products separately. DRAP has classified the batch as spurious or falsified, although its public notice does not explain whether investigators found evidence of deliberate misrepresentation. The distinction matters because an unauthorized supply route does not, by itself, prove that a medicine is counterfeit.
What the drug does, and how it must travel
Sandostatin LAR contains octreotide acetate. Doctors prescribe it for acromegaly, a condition in which the body makes too much growth hormone, and to manage symptoms of certain neuroendocrine tumors. Patients receive the long-acting form once every four weeks.
nps
Handling rules are strict. Ireland’s medicines regulator publishes product information for the 20 mg pack that calls for refrigeration at 2°C to 8°C, the original packaging to block light and no freezing. The Irish product information also permits storage below 25°C on the day of injection. DRAP has not said how the Pakistani batch travelled or where anyone stored it.
hpra
DRAP warned that the batch could cause treatment failure, adverse health effects, or other unknown safety problems. A box cannot vouch for its own journey.
The public notice leaves several critical questions unanswered.
It does not say how many packs entered Pakistan or which cities received them. It does not name the importer, distributor, or pharmacy that handled the stock. It does not say where the batch crossed the border.
Nouveaux Pharma says it never supplied the batch through Pakistan’s authorized channels. DRAP has now alerted inspectors to its reported presence. What remains unknown is who brought it into the country, who handled it and how far it travelled before authorities intervened.
What DRAP wants people to do
- Patients: Read the batch number on the packaging before any injection. If it says 380531, do not use it. Call a physician or pharmacist for guidance on an authorized replacement.
- Hospitals, clinics, and pharmacies: Check inventories and procurement sources closely.
- Healthcare professionals and patients: Report suspected adverse reactions or quality problems to DRAP’s National Pharmacovigilance Centre.
- Consumers: Buy medicines only from licensed pharmacies and authorized retailers.
DRAP’s field force now has to follow one batch through a supply chain that has not yet explained itself. The regulator has not said whether any patient has already received an injection from it.






